Cargando…

Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19

BACKGROUND: After its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce. METHODS: We included immunocompetent indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Thibeault, Charlotte, Bardtke, Lara, Vanshylla, Kanika, di Cristanziano, Veronica, Eberhardt, Kirsten A., Stubbemann, Paula, Hillus, David, Tober-Lau, Pinkus, Mukherjee, Parnika, Münn, Friederike, Lippert, Lena J., Helbig, Elisa T., Lingscheid, Tilman, Steinbeis, Fridolin, Mittermaier, Mirja, Witzenrath, Martin, Zoller, Thomas, Klein, Florian, Sander, Leif E., Kurth, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243822/
https://www.ncbi.nlm.nih.gov/pubmed/36881474
http://dx.doi.org/10.1172/jci.insight.166711
_version_ 1785054506529062912
author Thibeault, Charlotte
Bardtke, Lara
Vanshylla, Kanika
di Cristanziano, Veronica
Eberhardt, Kirsten A.
Stubbemann, Paula
Hillus, David
Tober-Lau, Pinkus
Mukherjee, Parnika
Münn, Friederike
Lippert, Lena J.
Helbig, Elisa T.
Lingscheid, Tilman
Steinbeis, Fridolin
Mittermaier, Mirja
Witzenrath, Martin
Zoller, Thomas
Klein, Florian
Sander, Leif E.
Kurth, Florian
author_facet Thibeault, Charlotte
Bardtke, Lara
Vanshylla, Kanika
di Cristanziano, Veronica
Eberhardt, Kirsten A.
Stubbemann, Paula
Hillus, David
Tober-Lau, Pinkus
Mukherjee, Parnika
Münn, Friederike
Lippert, Lena J.
Helbig, Elisa T.
Lingscheid, Tilman
Steinbeis, Fridolin
Mittermaier, Mirja
Witzenrath, Martin
Zoller, Thomas
Klein, Florian
Sander, Leif E.
Kurth, Florian
author_sort Thibeault, Charlotte
collection PubMed
description BACKGROUND: After its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce. METHODS: We included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike–reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization. RESULTS: Patients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence. CONCLUSION: Dexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization. FUNDING: Berlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices.
format Online
Article
Text
id pubmed-10243822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-102438222023-06-07 Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19 Thibeault, Charlotte Bardtke, Lara Vanshylla, Kanika di Cristanziano, Veronica Eberhardt, Kirsten A. Stubbemann, Paula Hillus, David Tober-Lau, Pinkus Mukherjee, Parnika Münn, Friederike Lippert, Lena J. Helbig, Elisa T. Lingscheid, Tilman Steinbeis, Fridolin Mittermaier, Mirja Witzenrath, Martin Zoller, Thomas Klein, Florian Sander, Leif E. Kurth, Florian JCI Insight Clinical Medicine BACKGROUND: After its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce. METHODS: We included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike–reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization. RESULTS: Patients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence. CONCLUSION: Dexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization. FUNDING: Berlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices. American Society for Clinical Investigation 2023-04-24 /pmc/articles/PMC10243822/ /pubmed/36881474 http://dx.doi.org/10.1172/jci.insight.166711 Text en © 2023 Thibeault et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Medicine
Thibeault, Charlotte
Bardtke, Lara
Vanshylla, Kanika
di Cristanziano, Veronica
Eberhardt, Kirsten A.
Stubbemann, Paula
Hillus, David
Tober-Lau, Pinkus
Mukherjee, Parnika
Münn, Friederike
Lippert, Lena J.
Helbig, Elisa T.
Lingscheid, Tilman
Steinbeis, Fridolin
Mittermaier, Mirja
Witzenrath, Martin
Zoller, Thomas
Klein, Florian
Sander, Leif E.
Kurth, Florian
Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
title Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
title_full Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
title_fullStr Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
title_full_unstemmed Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
title_short Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
title_sort short- and long-term t cell and antibody responses following dexamethasone treatment in covid-19
topic Clinical Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243822/
https://www.ncbi.nlm.nih.gov/pubmed/36881474
http://dx.doi.org/10.1172/jci.insight.166711
work_keys_str_mv AT thibeaultcharlotte shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT bardtkelara shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT vanshyllakanika shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT dicristanzianoveronica shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT eberhardtkirstena shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT stubbemannpaula shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT hillusdavid shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT toberlaupinkus shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT mukherjeeparnika shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT munnfriederike shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT lippertlenaj shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT helbigelisat shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT lingscheidtilman shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT steinbeisfridolin shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT mittermaiermirja shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT witzenrathmartin shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT zollerthomas shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT kleinflorian shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT sanderleife shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19
AT kurthflorian shortandlongtermtcellandantibodyresponsesfollowingdexamethasonetreatmentincovid19